

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N94ABE2F8853EN.html>

Date: March 2022

Pages: 46

Price: US\$ 3,500.00 (Single User License)

ID: N94ABE2F8853EN

Abstracts

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - N-sulphoglucosamine sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccharidosis III.

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 5 respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) and Alzheimer's Disease.

The latest report N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2022, outlays comprehensive information on the N Sulphoglucosamine Sulphohydrolase

(Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1)

The report reviews N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics and enlists all their major and minor projects

The report assesses N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics

based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Overview

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Companies Involved in Therapeutics Development

Abeona Therapeutics Inc

Amicus Therapeutics Inc

ArmaGen Inc

Denali Therapeutics Inc

Esteve Pharmaceuticals SA

JCR Pharmaceuticals Co Ltd

Lysogene SAS

Tega Therapeutics Inc

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Drug Profiles

AGT-184 - Drug Profile

Product Description

Mechanism Of Action

History of Events

DNL-126 - Drug Profile

Product Description

Mechanism Of Action

History of Events

EGT-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate SGSH for Mucopolysaccharidosis Type IIIA - Drug Profile

Product Description

Mechanism Of Action

History of Events

JR-441 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LYSSAF-302 - Drug Profile

Product Description

Mechanism Of Action

History of Events

rebisuffigene etisparvovec - Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Enzyme to Replace Sulphamidase for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Drug Profile

Product Description

Mechanism Of Action

History of Events

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Dormant Products

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Discontinued Products

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Product Development Milestones

Featured News & Press Releases

Feb 24, 2022: Lysogene provides update on efficacy, safety and timelines of the AAVance Phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPSIIIA

Feb 11, 2022: Lysogene reports additional positive biomarker data with LYS-SAF302 presented at the WORLDSymposium 2022

Feb 03, 2022: JCR pharmaceuticals to present posters on JR-441 at the 18th annual WORLDSymposium 2022

Jan 21, 2022: EC grants orphan drug designation to JR-441 for the treatment of

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Deve...

mucopolysaccharidosis type III A (MPS IIIA)

Nov 17, 2021: Abeona Therapeutics announces presentation on pivotal Transpher A study of ABO-102 in MPS IIIA at the 14th ICIEM Conference

Oct 13, 2021: Abeona Therapeutics announces clinical data presentations at upcoming scientific congresses

Jul 28, 2021: Abeona Therapeutics announces successful Type B meeting with U.S. FDA for ABO-102 AAV-based gene therapy in Sanfilippo Syndrome Type A (MPS IIIA)

Jul 26, 2021: Abeona Therapeutics announces new MRI data showing increased brain volume in young patients with Sanfilippo Syndrome Type A (MPS IIIA) after treatment with ABO-102 gene therapy

Feb 15, 2021: Lysogene reports LYS-SAF302 biomarker data presented at the WORLDSymposium 2021

Feb 12, 2021: New positive interim data on ABO-102 presented at WORLDSymposium

Feb 02, 2021: Abeona Therapeutics announces clinical investigator webinar to review ABO-102 Clinical Data presented at the 17th Annual WORLDSymposium

Dec 28, 2020: Lysogene reports positive biomarker data with LYS-SAF302

Dec 21, 2020: Abeona Therapeutics announces acceptance of late-breaker abstracts highlighting new clinical data for novel AAV-based gene therapies including rebisufligene etisparvovec at WORLDSymposium

Oct 15, 2020: Lysogene provides update on the AAVance clinical trial evaluating LYS-SAF302 in patients with MPS IIIA

Jun 05, 2020: Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Abeona Therapeutics Inc, 2022

Pipeline by Amicus Therapeutics Inc, 2022

Pipeline by ArmaGen Inc, 2022

Pipeline by Denali Therapeutics Inc, 2022

Pipeline by Esteve Pharmaceuticals SA, 2022

Pipeline by JCR Pharmaceuticals Co Ltd, 2022

Pipeline by Lysogene SAS, 2022

Pipeline by Tega Therapeutics Inc, 2022

Dormant Projects, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: N Sulphoglucosamine Sulphohydrolase (Sulfo-glucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N94ABE2F8853EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N94ABE2F8853EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970